Angelman Syndrome Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – PTC Therapeutics, Ovid Therapeutics, Sarepta Therapeutics

DelveInsight Business Research LLP

DelveInsight’s “Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Highlights 

• Key Companies working on Angelman Syndrome include Ovid Therapeutics

• GeneTx Biotherapeutics, PTC Therapeutics, Sarepta Therapeutics, StrideBio and many others 

• Key Therapies included in the Angelman Syndrome market include NNZ-2591, ION582,  minocycline and many others 

Angelman Syndrome Overview

Angelman syndrome or Angelman’s syndrome(AS) is a genetic disorder that mainly affects the nervous system.Symptoms include a small head and a specific facial appearance, severe intellectual disability, developmental disability, limited to no functional speech, balance and movement problems, seizures, and sleep problems.Children usually have a happy personality and have a particular interest in water.The symptoms generally become noticeable by one year of age.

Angelman syndrome is due to a lack of function of part of chromosome 15, typically due to a new mutation rather than one inherited. Most often it is due to a deletion or mutation of the UBE3A gene on that chromosome.Occasionally it is due to the inheritance of two copies of chromosome 15 from the father and none from the mother (paternal uniparental disomy).As the father’s versions are inactivated by a process known as genomic imprinting, no functional version of the gene remains.Diagnosis is based on symptoms and possibly genetic testing.

Angelman Syndrome  Epidemiology Insights

• According to the National Organization for Rare Disorders, Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delay and learning disabilities; absence or near absence of speech; inability to coordinate voluntary movements (ataxia); tremulousness with jerky movements of the arms and legs and a distinct behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling.

• People with Angelman syndrome have developmental problems that become noticeable by the age of 6 – 12 months. Other common signs and symptoms usually appear in early childhood like walking and balance disorders, gastrointestinal issues, seizures and little to no speech.

• According to the Angelman Syndrome Foundation (2022), Angelman syndrome is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene in the 15th chromosome derived from the mother.

• A diagnosis of Angelman syndrome may be made based upon a detailed patient history, a thorough clinical evaluation and identification of characteristic findings. About 80% of cases can be confirmed through a variety of specialized blood tests such as DNA methylation. Fluorescent in situ hybridization (FISH) or, most commonly, microarray chromosome analysis can detect the characteristic deletion of chromosome 15q11-q13 in cells of the body.

Click here to learn more about the Angelman Syndrome Market Landscape

The Report Covers the Angelman Syndrome  Epidemiology Segmented by:

• Angelman Syndrome  prevalent cases 

• Angelman Syndrome  incident cases 

• Angelman Syndrome  treatment cases 

• Angelman Syndrome-diagnosed cases 

Angelman Syndrome Market Outlook 

The Angelman Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Angelman Syndrome market trends by analyzing the impact of current Angelman Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Angelman Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Angelman Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Angelman Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Angelman Syndrome Market

• Ovid Therapeutics

• GeneTx Biotherapeutics, 

• PTC Therapeutics, 

• Sarepta Therapeutics, 

• StrideBio

And many others

Angelman Syndrome Therapies Covered and Analyzed in the Report

•  ISA-720

• SII-YFV

•  Stamaril 

And many others 

Learn more about the Key Companies and Emerging Therapies in the Angelman Syndrome Market

Table of Contents 

1.  Key Insights 

2.  Angelman Syndrome  Introduction 

3.  Executive Summary of Angelman Syndrome            

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Angelman Syndrome  Emerging Therapies

7.  Angelman Syndrome  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Angelman Syndrome Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services